747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors.
Saved in:
| Title: | 747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. |
|---|---|
| Authors: | Falchook, G.S.1 (AUTHOR), Fu, S.2 (AUTHOR), Lemech, C.3 (AUTHOR), Mckean, M.A.4 (AUTHOR), Azad, A.A.5 (AUTHOR), Gan, H.K.6 (AUTHOR), Sommerhalder, D.7 (AUTHOR), Wang, J.S.8 (AUTHOR), Tan, T.J.Y.9 (AUTHOR), Chee, C.E.10 (AUTHOR), Barve, M.11 (AUTHOR), Moser, J.12 (AUTHOR), Mooney, J.13 (AUTHOR), Acuff, N.13 (AUTHOR), Wang, R.14 (AUTHOR), Marina, N.14 (AUTHOR), Abbadessa, G.14 (AUTHOR), Streit, M.14 (AUTHOR), Ramusovic, S.15 (AUTHOR), Meniawy, T.16 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS885-S886. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.873 |
